Abstract 5822
Background
The real life experience in clinical arena can be challenging for student nurses, to cope with the patients’ suffering, to provide care, to communicate with them and their caregivers as death approaches .It is essential to understand student nurses’ feelings when confronted a dying patient, so that specific training, consultation and empowerment give them prior to their clinical placement. However, there has been little research in Greece on student nurses’ experience when facing care of patients and their caregivers in the last days of life.The purpose of this study was to explore undergraduate student nurse’s experience facing death and dying of a patient during their clinical practice.
Methods
A qualitative, descriptive design was used. Qualitative data were collected in June 2018 from 4th -year nursing students’ of Nursing School of National and Kapodistrian University of Athens. Experiences were collected through written reflections to obtain data about their experience when cared for a serious ill patient and when delivered their care to a dying patient and their caregivers. A content analysis of their comments was carried out.
Results
From 101 undergraduated nurses 42 answered in open-ended question “Please describe the death experience of a patient during your clinical practice”. The response rate was 41,6%.The average age of the students was 22.Nursing students’ comments revealed concerns on handling the family/caregivers of the dying patient, their willingness to care for body of the dying, expressing their emotions such as sadness, describing death experience using medical terminology and using their previous personal experiences and knowledge to handle with . Thus five categories were emerged, the concept of “family/caregivers issues” “participation in the care of the dying” “description of the event using medical terminology”, “expressing emotions positive or negative” and “referring to their previous experience and knowledge” respectively.
Conclusions
Study’s findings highlighted the influence of knowledge, personal attitudes and clinical stressors that student nurses faced in a clinical practice when they were training in palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract